ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Immunological Complications of Therapy Poster (1516–1529)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

Abstract Number: 1516
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Abstract Number: 1517
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Abstract Number: 1518
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Abstract Number: 1519
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
Abstract Number: 1520
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Abstract Number: 1521
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Abstract Number: 1522
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Abstract Number: 1523
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
Abstract Number: 1524
COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
Abstract Number: 1525
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Abstract Number: 1526
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Abstract Number: 1527
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Abstract Number: 1528
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
Abstract Number: 1529
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences